Market Intelligence, Clinical Progress, and High-Purity Reagents for Hematology, Malaria, and Erythroid-Targeting Therapeutics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GYPB/CD235b drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GYPB ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View GYPB Products |
| Gene Delivery | GYPB Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Conformationally intact surface display. |
View GYPB Products |
| Benchmark Ab | Anti-GYPB Recombinant Antibody Recombinant positive control for flow cytometry and binding assays. |
View GYPB Products |
| Validator | GYPB siRNA Set For knockdown verification in erythroid progenitor cell lines. |
View GYPB Products |
| Related Target A | GYPA (CD235a) High-homology counter-screening target to ensure GYPB-specific binding and avoid general hemolysis. |
View GYPA Products |
| Related Target B | CD47 Erythroid marker of self; co-expressed regulator of macrophage clearance. |
View CD47 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GYPA vs. GYPB Cross-Reactivity | Highly purified GYPA and GYPB ECD proteins available; sequence-verified to guarantee correct extracellular domain differentiation. |
| Native Glycosylation Dependencies | Expressed exclusively in HEK293 mammalian hosts to preserve complex sialylation crucial for physiological ligand binding. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Validated siRNA included for specificity checks in target-knockdown assays. |
Live GYPB/CD235b R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Glycophorin B (GYPB/CD235b) is carving a highly specialized niche in hematology, infectious disease, and targeted drug delivery. Primarily recognized as a major sialoglycoprotein on the erythrocyte membrane, GYPB is a critical entry receptor for Plasmodium falciparum (specifically interacting with erythrocyte-binding ligand 1, EBL-1). Current R&D is shifting focus from basic blood-group typing toward utilizing GYPB as a selective portal for erythroid-specific drug delivery, tolerogenic antigen carrier systems, and malaria-blocking therapeutics.
As next-generation biologics enter development, the primary objective is achieving strict selectivity over the highly abundant Glycophorin A (GYPA/CD235a). Because GYPA is heavily expressed, therapies targeting glycophorins must distinguish between the two to prevent massive, off-target hemolysis while maintaining high-affinity binding to GYPB for target-specific applications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies | Academic Institutes, Biopharma | Malaria Prophylaxis, Erythroleukemia | Selectivity Assay (Need high-purity GYPB vs. GYPA ECD-Fc to confirm no cross-reactivity) |
| Erythroid-Targeting Conjugates | Targeted Delivery Startups | Autoimmune Tolerance, Enzyme Replacement | Binding Kinetics (Need HEK293-expressed GYPB to preserve native sialylation) |
| Recombinant Decoy Proteins | Infectious Disease Consortia | Severe Malaria (Plasmodium Blocking) | High-affinity competition assays (Need sequence-verified, low-endotoxin ECD proteins) |